|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:775-776
© 2006 The American Association for Thoracic Surgery
Editorial |
Cleveland Clinic Foundation, Cleveland, Ohio
Received for publication November 11, 2005; accepted for publication November 18, 2005. * Address for reprints: Nicholas G. Smedira, MD, Cleveland Clinic Foundation, 9500 Euclid Avenue Desk F24, Cleveland, OH 44195 (Email: smedirn{at}ccf.org).
As of August 5, 2005 there were 96,189 patients awaiting organ transplantation. During 2004 only 27,036 transplants were performed, highlighting a growing disparity between patients listed and organs available. The United Network for Organ Sharing (UNOS) is charged with coordinating the sharing of organs to ensure fairness and optimal utilization, and they also monitor the outcomes of all listed and transplanted patients. This wealth of information, which is accessible to the medical community and patients, was analyzed by Dr. Mokadam and colleagues,
1
and as a result, they have raised concerns about the welfare of patients listed as status 2 (not inotrope-dependent, usually at home; patients listed as status 1A are hospitalized on devices or inotropes and patients listed as status 1B are on inotropes) during their prolonged wait for a heart transplant. Of the 1265 patients analyzed, 30% deteriorated and 10% died. Before responding to these concerns, I would like to take a closer look at how patients are doing while waiting for a heart transplant.
Since 1994, there has been a dramatic and unanticipated decline in the annual number of heart transplants performed in the United States. As reported by UNOS, during the past decade, heart transplants have been declining at a rate of 1% to 2% per year from a peak of 2528 in 1995 to 2016 in 2004. Arguing against donor shortages as the cause, the number of patients listed annually also declined from a peak of 4079 in 1998 to 2802 in 2002. There has also been a shortening of the aggregate waiting time despite news to the contrary. In Mokadam's review the median wait time for patients listed as status 2 was 406 days.
This information is accurate but somewhat misleading. UNOS presents times as "time to transplant" and "waiting time before transplant." Time to transplant includes active and inactive time; waiting time is only active time. A patient may be inactivated for many reasonstoo sick (early after left ventricular assist device [LVAD] insertion), too well, psychosocial, and personaland physicians are reluctant to remove the patients from the list because they will lose their accumulated time on the list. The number of patients classified as "temporarily inactive" at the end of the calendar year increased over the decade from 33% to 48% of patients listed. Figure 1 shows the time to transplant with patients listed as status 2 waiting substantially longer; Figure 2 shows a substantial reduction in waiting times when only active time is considered. Currently UNOS does not tabulate the reasons for inactive listing or which status level is more commonly inactive. It makes little sense to me to discuss waiting times unless this is when you are actively looking for a donor organ for the patient.
|
|
|
Should we consider randomizing patients listed as status 2? I have not seen a protocol to comment on. The reason this question is being asked by transplant physicians is because at 1 and 2 years after being listed as status 2, 50% and 20% of patients, respectively, are alive without transplantation or deterioration. Rather than a trial, an effort should be made to understand why some patients remain clinically stable after listing.
The transplant community should take great pride in the advances in cardiovascular medicine that have reduced the number of patients needing to be actively listed, reduced the waiting time for those listed, improved the safety of patients awaiting transplantation, and developed an allocation scheme that accurately identifies patients at greatest risk of dying. Further refinement of medical therapies and modifications of the allocation system should be implemented if they reduce the aggregate mortality for all patients requiring a heart transplant.3
| See related article on page 925.
|
Acknowledgments
The author thanks Drs Randall C. Starling and James B. Young for their assistance in the preparation of this editorial.
References
Related Article
This article has been cited by other articles:
![]() |
H. Kamiya, A. Koch, F.-U. Sack, P. Akhyari, A. Remppis, T. J. Dengler, M. Karck, and A. Lichtenberg Who needs 'bridge' to transplantation in the presence of the Eurotransplant high-urgency heart transplantation program? Eur. J. Cardiothorac. Surg., December 1, 2008; 34(6): 1129 - 1133. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lietz and L. W. Miller Improved Survival of Patients With End-Stage Heart Failure Listed for Heart Transplantation: Analysis of Organ Procurement and Transplantation Network/U.S. United Network of Organ Sharing Data, 1990 to 2005 J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1282 - 1290. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |